Companies in #Obesity and Metabolic Disease

Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapeutics that activate innate homeostatic pathways — including bitter taste receptors (TAS2R) — to treat metabolic and inflammatory disease. Its lead candidate ARD-101 targets hyperphagia in Prader-Willi syndrome; the Phase 3 HERO trial was voluntarily paused in February 2026 and terminated, and the FDA lifted its clinical hold in October 2026, leaving the programme awaiting a redesigned Phase 3 and a lower-dose resumption. A second programme, ARD-201, is in development for obesity.

Enveda is an AI-driven drug discovery company that reads nature's untapped chemistry through metabolomics and machine learning to discover small-molecule medicines roughly four times faster than the industry average. Its pipeline spans obesity and metabolic disease, immunology and inflammation, fibrosis and neurosensory disorders, and the company has raised more than $845 million since 2019.